For a hedged play on Incyte (INCY), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Jun 15, 2018 $65 covered call for a net debit in the $63.24 area. That is also the break-even stock price for the covered call. …
This suggests that analysts have very recently bumped up their estimates for INCY, giving the stock a Zacks Earnings ESP of +40.11% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP …
Add it all up, and the stock seems like a terrific bargain -- until you consider an important lesson Merck and Incyte recently learned the hard way. In short, you …
With no debt on the balance sheet and $1.54 bn in 2017 sales, Incyte is still a "sensible" buying opportunity even as its stock is up from the $80.85 53-wk low on 2/9/18. Incyte has a diverse pipeline of JAK1/JAK2, IDO1, PI3K-delta, and …
The Phase 3 trail was to determine the effectiveness of Incyte Corporation’s epacadostat in treating patients with unresectable or metastatic melanoma in combination with Merck & Co., Inc.’s (NYSE:MRK) KEYTRUDA. Unfortunately …
For a hedged play on Incyte (INCY), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Jun 15, 2018 $65 covered call for a net debit in the $63.31 area. That is also the break-even stock price for the covered call. …
SmarTrend identified a Downtrend for Incyte Corp (NASDAQ:INCY) on March 19th, 2018 at $87.42. In approximately 4 weeks, Incyte Corp has returned 19.50% as of today's recent price of $70.37. Incyte Corp share prices have moved …
Incyte has gapped open sharply lower this morning and is now down 18.37 at $64.69 on strong volume. The stock has tumbled to a new low for the year.
Biotech is not for the faint of heart. About 90% of drugs and therapies tested fail to make it to market. Even drugs with promising phase 2 data are up against huge odds of failure -- as Incyte (NASDAQ: INCY) shareholders were reminded …